Endex 19

Hauptinformation

  • Handelsname:
  • Endex® 19,5% ad us. vet., orale Suspension
  • Darreichungsform:
  • 5% ad us. vet., orale Suspension
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Endex® 19,5% ad us. vet., orale Suspension
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Oral anwendbares Breitband-Anthelminthikum gegen Nematoden und Leberegelbefall bei Rindern

Weitere Informationen

Status

  • Quelle:
  • Institut für Veterinärpharmakologie
  • Zulassungsnummer:
  • 51377
  • Letzte Änderung:
  • 03-11-2018

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Endex

19,5% ad us. vet., orale Suspension

Elanco Tiergesundheit AG

Oral anwendbares Breitband-Anthelminthikum gegen Nematoden und

Leberegelbefall bei Rindern

ATCvet: QP52AE51

Zusammensetzung

1 ml Suspension enthält:

Wirkstoff: Triclabendazol 120 mg, Levamisolhydrochlorid 75 mg. Konservierungsmittel:

E 210, E 216, E 218. Antioxidantien: E 223. Excipiens ad suspensionem

Fachinformationen Wirkstoffe (CliniPharm)

Levamisol - Triclabendazol

Eigenschaften / Wirkungen

Levamisol wirkt gegen Nematoden und Triclabendazol gegen Leberegel. Der

Wirkmechanismus von Levamisol beruht auf der cholinergen Aktivität, die zu spastischen

Lähmungen der Nematoden führt. Ausserdem hemmt Levamisol die Fumarat-Reduktase.

Pharmakokinetik

Levamisol und Triclabendazol werden nach oraler Verabreichung rasch resorbiert. Das

resorbierte Triclabendazol wird sehr schnell zu Sulfoxiden und Sulfonen oxidiert. Maximale

Plasmakonzentrationen von Levamisol werden bereits nach 0,5 - 1 Stunde und für

Triclabendazol 24 - 36 Stunden nach der Verabreichung erreicht. Die Ausscheidung von

Levamisol erfolgt über den Urin und Kot und diejenige von Triclabendazol hauptsächlich

über den Kot.

Indikationen

Endex 19.5% eignet sich zur gleichzeitigen Behandlung reifer und sich entwickelnder

unreifer Stadien von Magenwürmern (Haemonchus, Ostertagia, T. axei), Darmwürmern

(Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum) und

Lungenwürmern (Dictyocaulus) sowie allen Formen der Infektion durch den grossen

Leberegel (frühe unreife, unreife und geschlechtsreife Stadien von Fasciola hepatica und

F. gigantica) bei Rindern.

Endex 19,5% wird oral mit Hilfe der üblichen Eingabegeräte oder einer Plastikspritze

verabreicht.

Empfohlene Dosis

12,0 mg Triclabendazol / kg Körpergewicht

7,5 mg Levamisolhydrochlorid / kg Körpergewicht

Praktische Dosierungsanleitung

1 ml/10 kg Körpergewicht.

Körpergewicht

Dosierung

50 kg

5,0 ml

100 kg

10,0 ml

150 kg

15,0 ml

200 kg

20,0 ml

250 kg

25,0 ml

300 kg

30,0 ml

für jeweils 50 kg mehr5,0 ml

Behandlungsprogramm

Endex 19.5% wird bei gleichzeitigem Befall mit Nematoden und grossem Leberegel

verabreicht.

Die Behandlung vor Beginn der Weidesaison beseitigt Würmer, die im Tier überwintert

haben und verhindert eine Verseuchung der Weide.

Die Behandlung während der Weidezeit eliminiert inzwischen erworbene Infektionen und

verringert die Kontamination der Weide mit Wurmeiern, die später zu Infektionen und

Erkrankungen führen würden.

Die Behandlung nach der Weideperiode wird empfohlen, um inzwischen neu erworbene

Infektionen zu eliminieren.

-Alle zugekauften Tiere sollten behandelt werden, bevor sie zur Herde stossen.

Anwendungseinschränkungen

Kontraindikationen

Das Produkt ist gegen geschlechtsreife Ostertagia-Stadien und sich entwickelnde Larven

wirksam. Es ist aber nicht zur Bekämpfung inhibierter Larven indiziert.

Vorsichtsmassnahmen

Keine.

Unerwünschte Wirkungen

VetVigilance: Pharmacovigilance-Meldung erstatten

Überdosierung kann zu vorübergehenden Nebenwirkungen führen (Muskelzittern,

Speichelfluss).

Essbare Gewebe: 28 Tage. Milch: 12 Tage, Behandlungen während der Trächtigkeit

sollten spätestens 7 Tage vor dem Abkalben erfolgen.

Wechselwirkungen

Keine bekannt.

Sonstige Hinweise

Nur für Tiere. Für Kinder unzugänglich aufbewahren. Nach Gebrauch Hände waschen.

Jegliche Verunreinigung mit dem Produkt oder dem leeren Behälter von stehenden und

fliessenden Gewässern sowie Wasserläufen vermeiden. Entleerte Behälter unschädlich

beseitigen. Bei Raumtemperatur (15 - 25°C) aufbewahren. Vor Feuchtigkeit, Frost und

Hitze schützen. Vor Gebrauch gut schütteln. Verabreichungsspritze vor und nach

Gebrauch gut reinigen.

Packungen

Flasche zu 800 ml.

Abgabekategorie: B

Swissmedic Nr. 51'377

Informationsstand: 03/2006

Dieser Text ist behördlich genehmigt.

20-3-2019

March 19, 2019: Chinese Citizen Sentenced in Scheme to Sell Mislabeled Dietary Supplements

March 19, 2019: Chinese Citizen Sentenced in Scheme to Sell Mislabeled Dietary Supplements

March 19, 2019: Chinese Citizen Sentenced in Scheme to Sell Mislabeled Dietary Supplements

FDA - U.S. Food and Drug Administration

20-3-2019


Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019

Europe - EMA - European Medicines Agency

20-3-2019


Agenda - COMP agenda of the 19-21 March 2019 meeting

Agenda - COMP agenda of the 19-21 March 2019 meeting

Agenda - COMP agenda of the 19-21 March 2019 meeting

Europe - EMA - European Medicines Agency

20-3-2019

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 23 compounds belonging to different chemical groups. This opinion concerns eight out of the 23 compounds, which are currently authorised for use as flavours in food. The Panel concludes that the eight additives are safe for cats and dogs at the proposed use level: phenyl...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters). They are all currently authorised as flavours in food. The FEEDAP Panel was unable to perform the assessment of non‐2(c...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Probiotic Lactina® for chickens and rabbits

Probiotic Lactina® for chickens and rabbits

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the European Food Safety Authority Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Probiotic Lactina® for chickens for fattening and rabbits. The additive is a preparation containing viable cells of six strains of lactic acid bacteria intended for use in feed at the proposed dose of 2.5 × 109CFU/kg complete feedingstuffs. The ...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Assessment of the application for renewal of authorisation of Bonvital® (Enterococcus faecium DSM 7134) as a feed additive for weaned piglets and pigs for fattening

Assessment of the application for renewal of authorisation of Bonvital® (Enterococcus faecium DSM 7134) as a feed additive for weaned piglets and pigs for fattening

Published on: Tue, 19 Mar 2019 Bonvital® is the trade name for a feed additive based on Enterococcus faecium DSM 7134 currently authorised for use in piglets, pigs for fattening, sows, chickens for fattening, chickens reared for laying and minor poultry species. This opinion concerns the renewal of the authorisation of Bonvital® as a zootechnical additive for weaned piglets and pigs for fattening. The applicant is proposing to increase the minimum and maximum inclusion level of the additive in feed for ...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Hometown Food Company Recalls Two Production LOT Codes of Pillsbury® Unbleached All-Purpose 5lb Flour Due to Possible Health Risk

Hometown Food Company Recalls Two Production LOT Codes of Pillsbury® Unbleached All-Purpose 5lb Flour Due to Possible Health Risk

Please be advised the Hometown Food Company initiated a limited, voluntary retail-level recall on two specific lot codes of its Pillsbury® Unbleached All-Purpose 5 lb Flour (UPC 51500-22241) because it may be contaminated with Salmonella. Only Best If Used By Dates APR 19 2020 and APR 20 2020 are impacted.

FDA - U.S. Food and Drug Administration

23-2-2019

Umsetzung der einstimmigen Beschlüsse der Koordinierungsgruppe EMA/CMDh /439088/2017 vom 19.07.2017 und EMA/CMDh /848760/2018 vom 12.12.2018  betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Isotretinoin (orale Darreichungsformen)

Umsetzung der einstimmigen Beschlüsse der Koordinierungsgruppe EMA/CMDh /439088/2017 vom 19.07.2017 und EMA/CMDh /848760/2018 vom 12.12.2018 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Isotretinoin (orale Darreichungsformen)

Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Isotretinoin (orale Darreichungsformen) infolge der Europäischen PSUR Single Assessment Verfahren nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

20-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Europe - EMA - European Medicines Agency

9-2-2019

Birdseed Food Co. Issues Allergy Alert on Undeclared Cashews in Craft Granola Goldenola Turmeric & Ginger

Birdseed Food Co. Issues Allergy Alert on Undeclared Cashews in Craft Granola Goldenola Turmeric & Ginger

BIRDSEED FOOD CO. of Bend, OR is recalling Craft Granola Goldenola Turmeric & Ginger that was sold between the dates of 10/03/18 - 02/07/19, because it contains undeclared cashews. People who have an allergy or severe sensitivity to cashews run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

29-1-2019

Ausschreibung für den Anbau von Cannabis zu medizinischen Zwecken: 79 Bieter haben Angebote abgegeben, Zuschlagserteilung soll im 2. Quartal 2019 erfolgen

Ausschreibung für den Anbau von Cannabis zu medizinischen Zwecken: 79 Bieter haben Angebote abgegeben, Zuschlagserteilung soll im 2. Quartal 2019 erfolgen

Pressemitteilung Nr. 1/19

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

22-3-2019


Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 March 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 March 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 March 2019

Europe - EMA - European Medicines Agency

19-3-2019

Loxicom (Norbrook Laboratories (Ireland) Limited)

Loxicom (Norbrook Laboratories (Ireland) Limited)

Loxicom (Active substance: Meloxicam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2179 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/141/T/32

Europe -DG Health and Food Safety

19-3-2019

EU/3/18/2101 (TMC Pharma (EU) Limited)

EU/3/18/2101 (TMC Pharma (EU) Limited)

EU/3/18/2101 (Active substance: Setmelanotide) - Transfer of orphan designation - Commission Decision (2019)2155 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004764

Europe -DG Health and Food Safety

19-3-2019

EU/3/16/1703 (TMC Pharma (EU) Limited)

EU/3/16/1703 (TMC Pharma (EU) Limited)

EU/3/16/1703 (Active substance: Setmelanotide) - Transfer of orphan designation - Commission Decision (2019)2154 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004730

Europe -DG Health and Food Safety

19-3-2019

EU/3/16/1688 (TMC Pharma (EU) Limited)

EU/3/16/1688 (TMC Pharma (EU) Limited)

EU/3/16/1688 (Active substance: Setmelanotide) - Transfer of orphan designation - Commission Decision (2019)2153 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004734

Europe -DG Health and Food Safety

19-3-2019

EU/3/18/2052 (Dicerna Ireland Limited)

EU/3/18/2052 (Dicerna Ireland Limited)

EU/3/18/2052 (Active substance: Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues) - Transfer of orphan designation - Commission Decision (2019)2156 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004770

Europe -DG Health and Food Safety

19-3-2019

EU/3/10/823 (Amryt Pharmaceuticals Designated Activity Company)

EU/3/10/823 (Amryt Pharmaceuticals Designated Activity Company)

EU/3/10/823 (Active substance: Lomitapide) - Transfer of orphan designation - Commission Decision (2019)2152 of Tue, 19 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004233

Europe -DG Health and Food Safety

18-3-2019

EU/3/15/1584 (Diamond ROC EOOD)

EU/3/15/1584 (Diamond ROC EOOD)

EU/3/15/1584 (Active substance: Variant of recombinant human fibroblast growth factor 19) - Transfer of orphan designation - Commission Decision (2019)2148 of Mon, 18 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003801

Europe -DG Health and Food Safety

18-3-2019

EU/3/14/1329 (Diamond ROC EOOD)

EU/3/14/1329 (Diamond ROC EOOD)

EU/3/14/1329 (Active substance: Variant of recombinant human fibroblast growth factor 19) - Transfer of orphan designation - Commission Decision (2019)2147 of Mon, 18 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003809

Europe -DG Health and Food Safety

15-3-2019

EU/3/19/2139 (Clinical Network Services (NL) B.V.)

EU/3/19/2139 (Clinical Network Services (NL) B.V.)

EU/3/19/2139 (Active substance: Autologous adult live cultured osteoblasts) - Transfer of orphan designation - Commission Decision (2019)2105 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004280

Europe -DG Health and Food Safety

6-3-2019


Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide (avacopan), Treatment of granulomatosis with polyangiitis, 19/11/2014, Positive

Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide (avacopan), Treatment of granulomatosis with polyangiitis, 19/11/2014, Positive

Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide (avacopan), Treatment of granulomatosis with polyangiitis, 19/11/2014, Positive

Europe - EMA - European Medicines Agency

6-3-2019


Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide, Treatment of microscopic polyangiitis (avacopan), 19/11/2014, Positive

Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide, Treatment of microscopic polyangiitis (avacopan), 19/11/2014, Positive

Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide, Treatment of microscopic polyangiitis (avacopan), 19/11/2014, Positive

Europe - EMA - European Medicines Agency

4-3-2019

EU/3/19/2144 (Accelsiors CRO And Consultancy Services Ltd.)

EU/3/19/2144 (Accelsiors CRO And Consultancy Services Ltd.)

EU/3/19/2144 (Active substance: Poly(N-acetyl, N-arginyl)glucosamine) - Orphan designation - Commission Decision (2019)1736 of Mon, 04 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002552

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2135 (Enzyvant Therapeutics Ireland Limited)

EU/3/19/2135 (Enzyvant Therapeutics Ireland Limited)

EU/3/19/2135 (Active substance: Allogeneic cultured postnatal thymus-derived tissue) - Orphan designation - Commission Decision (2019)1727 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002975

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2134 (FGK Representative Service GmbH)

EU/3/19/2134 (FGK Representative Service GmbH)

EU/3/19/2134 (Active substance: 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester) - Orphan designation - Commission Decision (2019)1726 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002279

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2145 (Roche Registration GmbH)

EU/3/19/2145 (Roche Registration GmbH)

EU/3/19/2145 (Active substance: Risdiplam) - Orphan designation - Commission Decision (2019)1737 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001899

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2143 (Pharma Mar S.A.)

EU/3/19/2143 (Pharma Mar S.A.)

EU/3/19/2143 (Active substance: Lurbinectedin) - Orphan designation - Commission Decision (2019)1735 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001317

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2142 (3R Pharma Consulting GmbH)

EU/3/19/2142 (3R Pharma Consulting GmbH)

EU/3/19/2142 (Active substance: Losartan) - Orphan designation - Commission Decision (2019)1734 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002383

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2141 (Fondazione Telethon)

EU/3/19/2141 (Fondazione Telethon)

EU/3/19/2141 (Active substance: Lentiviral vector encoding human coagulation factor IX) - Orphan designation - Commission Decision (2019)1733 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002293

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2140 (Artemida Pharma Europe Limited)

EU/3/19/2140 (Artemida Pharma Europe Limited)

EU/3/19/2140 (Active substance: Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase) - Orphan designation - Commission Decision (2019)1732 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001793

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2139 (Clinical Network Services (UK) Ltd)

EU/3/19/2139 (Clinical Network Services (UK) Ltd)

EU/3/19/2139 (Active substance: Autologous adult live cultured osteoblasts) - Orphan designation - Commission Decision (2019)1731 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001655

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2138 (Common Services Agency (National Health Services - Scotland))

EU/3/19/2138 (Common Services Agency (National Health Services - Scotland))

EU/3/19/2138 (Active substance: Anti-Epstein Barr virus cytotoxic lymphocytes) - Orphan designation - Commission Decision (2019)1730 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002426

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2137 (Enzyvant Therapeutics Ireland Limited)

EU/3/19/2137 (Enzyvant Therapeutics Ireland Limited)

EU/3/19/2137 (Active substance: Allogeneic cultured postnatal thymus-derived tissue) - Orphan designation - Commission Decision (2019)1729 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002979

Europe -DG Health and Food Safety

28-2-2019

EU/3/19/2136 (Enzyvant Therapeutics Ireland Limited)

EU/3/19/2136 (Enzyvant Therapeutics Ireland Limited)

EU/3/19/2136 (Active substance: Allogeneic cultured postnatal thymus-derived tissue) - Orphan designation - Commission Decision (2019)1728 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002977

Europe -DG Health and Food Safety

25-2-2019


Orphan designation: Anetumab ravtansine, Treatment of ovarian cancer, 19/11/2018, Positive

Orphan designation: Anetumab ravtansine, Treatment of ovarian cancer, 19/11/2018, Positive

Orphan designation: Anetumab ravtansine, Treatment of ovarian cancer, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp, Treatment of multiple system atrophy, 19/11/2018, Positive

Orphan designation: Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp, Treatment of multiple system atrophy, 19/11/2018, Positive

Orphan designation: Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp, Treatment of multiple system atrophy, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth, Treatment of glioma, 19/11/2018, Positive

Orphan designation: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth, Treatment of glioma, 19/11/2018, Positive

Orphan designation: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth, Treatment of glioma, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Setmelanotide, Treatment of leptin receptor deficiency, 19/11/2018, Positive

Orphan designation: Setmelanotide, Treatment of leptin receptor deficiency, 19/11/2018, Positive

Orphan designation: Setmelanotide, Treatment of leptin receptor deficiency, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Etamsylate, Treatment of hereditary haemorrhagic telangiectasia, 19/11/2018, Positive

Orphan designation: Etamsylate, Treatment of hereditary haemorrhagic telangiectasia, 19/11/2018, Positive

Orphan designation: Etamsylate, Treatment of hereditary haemorrhagic telangiectasia, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast, Treatment of Duchenne muscular dystrophy, 19/11/2018, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast, Treatment of Duchenne muscular dystrophy, 19/11/2018, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast, Treatment of Duchenne muscular dystrophy, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor, Treatment of Duchenne muscular dystrophy, 19/11/2019, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor, Treatment of Duchenne muscular dystrophy, 19/11/2019, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor, Treatment of Duchenne muscular dystrophy, 19/11/2019, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Anti-GD2 monoclonal antibody 3F8 humanised, Treatment of neuroblastoma, 19/11/2018, Positive

Orphan designation: Anti-GD2 monoclonal antibody 3F8 humanised, Treatment of neuroblastoma, 19/11/2018, Positive

Orphan designation: Anti-GD2 monoclonal antibody 3F8 humanised, Treatment of neuroblastoma, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Lisocabtagene maraleucel, Treatment of primary mediastinal large-B-cell lymphoma, 19/11/2018, Positive

Orphan designation: Lisocabtagene maraleucel, Treatment of primary mediastinal large-B-cell lymphoma, 19/11/2018, Positive

Orphan designation: Lisocabtagene maraleucel, Treatment of primary mediastinal large-B-cell lymphoma, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Allogeneic faecal microbiota, pooled, Treatment of graft-versus-host-disease, 19/11/2018, Positive

Orphan designation: Allogeneic faecal microbiota, pooled, Treatment of graft-versus-host-disease, 19/11/2018, Positive

Orphan designation: Allogeneic faecal microbiota, pooled, Treatment of graft-versus-host-disease, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

22-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Europe - EMA - European Medicines Agency

22-2-2019


Orphan designation: Larotrectinib, Treatment of papillary thyroid cancer, 19/11/2018, Positive

Orphan designation: Larotrectinib, Treatment of papillary thyroid cancer, 19/11/2018, Positive

Orphan designation: Larotrectinib, Treatment of papillary thyroid cancer, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

22-2-2019


Orphan designation: Triheptanoin, Treatment of very long-chain acyl-CoA dehydrogenase deficiency, 19/06/2015, Positive

Orphan designation: Triheptanoin, Treatment of very long-chain acyl-CoA dehydrogenase deficiency, 19/06/2015, Positive

Orphan designation: Triheptanoin, Treatment of very long-chain acyl-CoA dehydrogenase deficiency, 19/06/2015, Positive

Europe - EMA - European Medicines Agency

21-2-2019


Orphan designation: Tideglusib, Treatment of fragile X syndrome, 19/03/2015, Withdrawn

Orphan designation: Tideglusib, Treatment of fragile X syndrome, 19/03/2015, Withdrawn

Orphan designation: Tideglusib, Treatment of fragile X syndrome, 19/03/2015, Withdrawn

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand, The treatment of pancreatic cancer, 19/11/2018, Positive

Orphan designation: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand, The treatment of pancreatic cancer, 19/11/2018, Positive

Orphan designation: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand, The treatment of pancreatic cancer, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: Larotrectinib, Treatment of glioma, 19/11/2018, Positive

Orphan designation: Larotrectinib, Treatment of glioma, 19/11/2018, Positive

Orphan designation: Larotrectinib, Treatment of glioma, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: fidanacogene elaparvovec, Treatment of haemophilia B, 19/11/2018, Positive

Orphan designation: fidanacogene elaparvovec, Treatment of haemophilia B, 19/11/2018, Positive

Orphan designation: fidanacogene elaparvovec, Treatment of haemophilia B, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: apraglutide, Treatment of short bowel syndrome, 19/11/2018, Positive

Orphan designation: apraglutide, Treatment of short bowel syndrome, 19/11/2018, Positive

Orphan designation: apraglutide, Treatment of short bowel syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, Treatment of cystic fibrosis, 19/11/2014, Positive

Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, Treatment of cystic fibrosis, 19/11/2014, Positive

Orphan designation: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid, Treatment of cystic fibrosis, 19/11/2014, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: human apotransferrin, Treatment of beta-thalassaemia intermedia and major, 19/11/2018, Positive

Orphan designation: human apotransferrin, Treatment of beta-thalassaemia intermedia and major, 19/11/2018, Positive

Orphan designation: human apotransferrin, Treatment of beta-thalassaemia intermedia and major, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive

Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive

Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate, Treatment of cystic fibrosis, 19/11/2018, Positive

Orphan designation: cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate, Treatment of cystic fibrosis, 19/11/2018, Positive

Orphan designation: cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate, Treatment of cystic fibrosis, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: propagermanium, Treatment of focal segmental glomerulosclerosis, 19/11/2018, Positive

Orphan designation: propagermanium, Treatment of focal segmental glomerulosclerosis, 19/11/2018, Positive

Orphan designation: propagermanium, Treatment of focal segmental glomerulosclerosis, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, Treatment of ATTR amyloidosis, 19/11/2018, Positive

Orphan designation: 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, Treatment of ATTR amyloidosis, 19/11/2018, Positive

Orphan designation: 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, Treatment of ATTR amyloidosis, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019

Besremi (AOP Orphan Pharmaceuticals AG)

Besremi (AOP Orphan Pharmaceuticals AG)

Besremi (Active substance: ropeginterferon alfa-2b) - Centralised - Authorisation - Commission Decision (2019)1455 of Tue, 19 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4128/00

Europe -DG Health and Food Safety

19-2-2019

Efavirenz

Efavirenz

Efavirenz (Active substance: efavirenz) - Centralised - Art 28 - (PSUR - Commission Decision (2019) 1514 of Tue, 19 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C//PSUSA/00001200/201804

Europe -DG Health and Food Safety

19-2-2019


Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Orphan designation: Imlifidase, Treatment of anti-glomerular basement membrane disease, 19/11/2018, Positive

Europe - EMA - European Medicines Agency